Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
Aging Cell · 2023
DOI: 10.1111/acel.13871 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Aging Cell, 2023. Verfasst von Stephanie A Schultz und 47 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Presenilin-1, Alzheimer Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Ann Romney Center for Neurologic Diseases, Boston, Massachusetts, USA.
- Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- INEBA, Buenos Aires, Argentina.
ORCID-Profile: Stephanie A Schultz, Lei Liu
Förderung
- NIA NIH HHS
- NIH HHS
- Alzheimer's Association
- National Institute on Aging
Zitieren
APA
Schultz, S. A., Shirzadi, Z., Schultz, A. P., Liu, L., Fitzpatrick, C. D., McDade, E., Barthelemy, N. R., Renton, A., Esposito, B., Joseph-Mathurin, N., Cruchaga, C., Chen, C. D., Goate, A., Allegri, R. F., Benzinger, T. L. S., Berman, S., Chui, H. C., Fagan, A. M., Farlow, M. R., …, & Dominantly Inherited Alzheimer Network Investigators (2023). Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease. Aging Cell. https://doi.org/10.1111/acel.13871
Vancouver
Schultz SA, Shirzadi Z, Schultz AP, Liu L, Fitzpatrick CD, McDade E, et al. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease. Aging Cell. 2023. doi:10.1111/acel.13871
BibTeX
@article{Schultz2023,
author = {Schultz, Stephanie A and Shirzadi, Zahra and Schultz, Aaron P and Liu, Lei and Fitzpatrick, Colleen D and McDade, Eric and Barthelemy, Nicolas R and Renton, Alan and Esposito, Bianca and Joseph-Mathurin, Nelly and Cruchaga, Carlos and Chen, Charles D and Goate, Alison and Allegri, Ricardo Francisco and Benzinger, Tammie L S and Berman, Sarah and Chui, Helena C and Fagan, Anne M and Farlow, Martin R and Fox, Nick C and Gordon, Brian A and Day, Gregory S and Graff-Radford, Neill R and Hassenstab, Jason J and Hanseeuw, Bernard J and Hofmann, Anna and Jack, Clifford R and Jucker, Mathias and Karch, Celeste M and Koeppe, Robert A and Lee, Jae-Hong and Levey, Allan I and Levin, Johannes and Martins, Ralph N and Mori, Hiroshi and Morris, John C and Noble, James and Perrin, Richard J and Rosa-Neto, Pedro and Salloway, Stephen P and Sanchez-Valle, Raquel and Schofield, Peter R and Xiong, Chengjie and Johnson, Keith A and Bateman, Randall J and Sperling, Reisa A and Chhatwal, Jasmeer P and Dominantly Inherited Alzheimer Network Investigators, Dominantly Inherited Alzheimer Network Investigators},
title = {Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease},
journal = {Aging Cell},
year = {2023},
doi = {10.1111/acel.13871}
}
EUVIMED